Table 6.

An update of nanoparticulate nanomedicine-based anticancer therapeutics clinical trials studies.

Nanoparticulate System	Drug/Therapeutic Agent	Type of Cancer	Findings	Clinical Trials Status	Reference
Liposomes	Doxorubicin	Primary and metastatic liver cancer	Well tolerated by patients (n = 18) with 33% response rate	FDA-approved	[322]
Albumin nanoparticles	Paclitaxel	Squamous cell carcinoma	Well tolerated by patients (n = 42) with 81% response rate	FDA-approved	[323]
Liposomes	Cisplatin	Advanced malignant tumors	51% clinical benefit with 11.1% partial response in patients (n = 12)	Active, phase II clinical trials	[324]
PEG and polyaspartate polymeric nanoparticles	Paclitaxel	Bile duct, pancreatic, gastric and colon cancer	30% stable disease and 5% responded well (n = 19)	Active, phase III clinical trials	[325]
Liposomes	Vincristine sulphate	Acute lymphoblastic lymphoma	22% complete and partial response (n = 36)	FDA-approved	[326]
Albumin nanoparticles (ABl-007)	Nanoparticle bound paclitaxel and free gemcitabine	Metastatic breast cancer	Well-tolerated and 81% response rate (n = 42), 8% complete response, and 42% complete response (n = 50)	FDA-approved	[327]
NK012 polymeric nanoparticles	SN-38 (Camptothecin analogue)	Solid tumors	9% partial response (n = 11)	Active, phase II clinical trials	[328]
Immunoliposomes	Doxorubicin and anti-EGFR	Advanced solid tumors	38% stable disease, 8% complete and partial response (n = 26)	Active, phase II clinical trials	[329]
Liposomes	Annamycin	Acute lymphoblastic leukemia	16% partial response (n = 31)	Active, phase II clinical trials	[330]
Liposomes	Vincristine sulphate	Acute lymphoblastic lymphoma	41% complete and partial response (n = 56)	FDA-approved	[331]
PEP02 liposomes	Irinotecan and Docetaxel	Gastro-esophageal adenocarcinoma and metastatic gastric	14% complete and partial response (n = 44)	FDA-approved	[332]
Polymeric CRLX101 nanoparticles	Camptothecin	Advanced solid tumors	64% stable disease (n = 44)	Active, phase II clinical trials	[333]
Lipid nanoparticles	VEGF and KSP siRNAs	Advanced solid tumors	42% stable disease (n = 24)	Limited progression of siRNAs into phase II	[240]
Cationic liposomes	wt human p53 plasmid	Advanced solid tumors	64% stable disease (n = 11)	Active, phase II clinical trials	[334]
Bind-014 coated nanoparticles	Docetaxel	Advanced solid tumors	12% complete and partial disease response (n = 52)	Active, phase I clinical trials	[335]
Lipid core nanoparticles	Paclitaxel	Epithelial ovarian sarcoma	43% progression free survival (n = 14)	Active, phase II clinical trials	[336]
NC-6004 micellar nanoparticles	Cisplatin	Advanced solid tumors	70% stable disease and 15% partial response (n = 22)	Active, phase III clinical trials	[337]
PEG protein conjugate	L-asparaginase	Lymphoblastic leukemia	77.8 complete response and 3.7% partial response, Overall survival of 50% or better (n = 162)	FDA-approved	[338]
PEG polymer micelles	Epirubicin	Advanced and recurrent solid tumors	53% stable disease and 5% partial response (n = 47)	Terminated (did not cross after phase I trials)	[339]
Liposomes	MRX34 (miR-34a)	Advanced solid tumors	13% stable disease and 68% partial response (n = 47)	Terminated	[340]
Activated carbon nanoparticles	Epirubicin	Breast cancer	No response	Terminated	[341]
DOTAP-cholesterol nanoparticles	TUSC2 plasmid	Lung cancer	23% partial response and stable disease (n = 31)	Terminated (did not cross after phase I trials)	[342]
CYT-6091 colloid PEGylated nanoparticles	Recombinant human TNF-α	Solid organ cancer	1% complete and partial response (n = 156)	Terminated (did not cross after phase I trials)	[324]
Rexin-G nanoparticles	Cytocidal cyclin G1 construct	Sarcoma and osteosarcoma	88% stable disease or partial response (n = 17)	Terminated (did not cross after phase II trials)	[343]